Bausch Health Companies | VRX - Selling And Administration Expenses


Bausch Health Companies reported $834M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Amgen USD 1.68B 40M Sep/2026
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
Bausch Health Companies USD 834M 67M Sep/2026
Biogen USD 752M 42.3M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Corcept Therapeutics USD 142.04M 14.86M Sep/2026
Danaher USD 2.16B 87M Sep/2026
Drreddys Laboratories INR 28.08B 13.61B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Pacira USD 950.8M 858.99M Sep/2026
Perrigo USD 271.7M 3.01B Sep/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 2.08B 2.04B Sep/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Zoetis USD 582M 10M Sep/2026